In our trial, women who received part of their chemotherapy via an IP route had a median survival time of 16 months longer than women who received only IV chemotherapy.

This is a significant improvement in survival for women with this disease, which is most often diagnosed at an advanced stage.

This is the longest survival reported to date for advanced ovarian cancer.

But now we have firm data showing we should use (it) in most women with advanced ovarian cancer who have had successful surgery to remove the bulk of their tumor.

I think it's a major step forward. There's no question about it.

The catheter allows us to bathe the entire abdominal area with a high concentration of chemotherapy for a long period of time, which appears to be better at destroying lingering cancer cells.